🇺🇸 BioCryst Pharmaceuticals, Inc.
Forum topic · BCRX · Company page: financials, ownership and filings
Join the discussion on BioCryst Pharmaceuticals, Inc.
Loading…
Results announced on 4 November 2026
BioCryst Pharmaceuticals, Inc. announced results on 4 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $180 million (up 13% from a year earlier) and net income of $38 million (up 194% from a year earlier).
Mutual funds: 185 funds hold $714 million
185 mutual funds in 1 country hold shares of BioCryst Pharmaceuticals, Inc. worth $714 million, about 28.6% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 92 funds added shares and 93 sold; on balance they bought $32 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.